Propel testing excellence with Mayo Clinic quality
Mayo Clinic Laboratories is a one-stop laboratory solution, offering commercial laboratories a vast testing menu, unparalleled customer service, and optimized processes. We work collaboratively with partners to assess their needs, providing the testing they need to expand into new areas and meet their business goals.
As the reference lab for Mayo Clinic, we’ve developed robust logistics and testing protocols applied uniformly for all specimens received, no matter their geographic origin. Whether you send us one test order or thousands, each sample receives the same treatment and level of care, ensuring superior results that help our partners better serve their clients.
“Our clients want personal experiences. They want someone to answer the phone. They want someone to provide answers when they're looking for results of a sample sent a couple days ago. and we deliver those answers.”
Angie Reese-Davis, director of operations, logistics, and specimen services, Mayo Clinic Laboratories
Our difference
News and updates
The latest
In this video, Dr. Vijay Ramanan shares perspectives on rational approaches to testing in the cognitive neurology, mild cognitive impairment, and dementia settings.
Today's Highlight's Include: US expected to authorize mix-and-match COVID booster shots, White House details plans to vaccinate 28M children age 5-11, and Facebook is reportedly changing its name.
In this episode of Lab Medicine Rounds, Joseph Yao, M.D., Associate Professor of Laboratory Medicine and Pathology and Medicine, and Assistant Professor of Microbiology at the Mayo Clinic, discusses lessons learned from navigating the current COVID-19 pandemic.
Mayo Clinic Laboratories’ call center has a new outgoing caller ID number for any follow up client communications.
William Morice II, M.D., Ph.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic and president of Mayo Clinic Laboratories, joins the "Answers From the Lab" podcast for his weekly leadership update with Bobbi Pritt, M.D. As cases of COVID-19 fall in some areas of the country and rise in others, Dr. Morice and Dr. Pritt review where the pandemic stands, and emphasize that now is not the time to let our guard down.
Cynthia Collie, a hospital account executive for Mayo Clinic Laboratories, focuses on connecting her clients with the right people, tools, and services to meet their needs and goals.
This week’s research roundup features: Autopsy validation of progressive supranuclear palsy-predominant speech/language disorder criteria.
In part three of the 50th Anniversary series, Mayo Clinic Laboratories looks further outside the walls of Mayo Clinic. With the belief that the latest in diagnostic testing should be available to any patient, no matter where they are located, the sales force was born.
Topic's Include: Covid Queries: Altered DNA and microchips, Mayo Clinic Minute: Flu during a pandemic, and COVID-19 media only news briefing: Kids, COVID-19 and fall festivities / tips for staying safe.
Today's Highlight's Include: Walz to announce plans Friday morning to address hospital capacity, expanding COVID rapid testing, hospitals brace for an onslaught this winter, from flu as well as COVID, and Mayo announces urgent need for O+ and O- blood types.
It can be hard to know when to use a rapid at-home COVID-19 test and how to interpret the results. Dr. Binnicker reviews the pros and cons of these tests, and explains when you need to get tested by a lab.
In a newly published study, a team from Mayo Clinic’s Advanced Diagnostics Laboratory has developed a mass spectrometry-based assay that’s able to detect COVID-19 (SARS-CoV-2) pathogens from human proteins with, remarkably, 98% sensitivity and 100% specificity. This is the first assay of its kind that can detect viral antigens “directly from clinical specimens” such as nasopharyngeal swabs. Mass spectrometry is a sensitive technique used to detect, identify, and quantitate molecules present in a sample.
This week’s research roundup features: Effect of urate-elevating inosine on early Parkinson disease progression: The SURE-PD3 randomized clinical trial.